Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19 A Randomized Clinical Trial

At 105 hospitals in the United States, Europe, and Asia, this randomized, open-label, phase 3 trial was conducted among 584 patients diagnosed with moderate COVID-19. The authors did not find a statistically significant difference in clinical status in patients who received a 10-day course of remdesivir compared with those received standard care. They did find a statistically significant difference in clinical status of those who received a 5-day course of remdesivir.